Global female infertility diagnosis and treatment market

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022

OrionOrion Market Research Market Research

t

TABLE OF CONTENTS 1. REPORT SUMMARY

Medical Devices

1.1.

RESEARCH METHODS AND TOOLS

1.2.

MARKET BREAKDOWN

1.2.1.

BY SEGMENTS

1.2.2.

BY GEOGRAPHY

1.2.3.

BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS 2.1.

DEFINITION

2.2.

ANALYST INSIGHTS & CURRENT MARKET TRENDS

2.2.1.

KEY FINDINGS

2.2.2.

RECOMMENDATION

2.2.3.

CONCLUSION

2.3.

REGULATIONS

2.3.1.

UNITED STATES

2.3.2.

EUROPEAN UNION

2.3.3.

CHINA

2.3.4.

INDIA

2.3.5.

REST OF THE WORLD

3. Female MARKET Infertility DETERMINANT Global Diagnosis and Treatment Market Research 3.1. MOTIVATORS and Analysis, 2015-2022 3.1.1.

CHANGING LIFE STYLE

A Report By-Orion Market Research 3.1.2.

OMR2017103

RISING TREND OF SURROGACY

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research 3.1.3.

INCREASING AGE

3.1.4.

NEW TECHNOLOGIES TO AVOID MULTIPLE EMBRYO IMPLANTS

3.1.5.

INCREASING IVF TREAMENT MARKET

3.1.6.

GROWING INFERTILITY RATE AMONG FEMALE

3.2.

RESTRAINTS

3.2.1.

HIGH COST OF TREATMENT

3.2.2.

INCREASING INCIDENCES OF TREATMENT FAILURES

3.2.3.

SOCIAL STIGMA RELATED TO INFERTILITY TREATMENT

3.3.

OPPORTUNITIES

3.3.1.

INCREASING MEDICAL TOURISM

3.3.2.

INCREASING AWARENESS AMONG PEOPLE

4. MARKET SEGMENTATION 4.1.

GLOBAL MALE INFERTILITY MARKET BY DIAGNOSIS

4.1.1.

OVULATION TESTING MARKET

4.1.2.

HYSTEROSALPINGOGRAPHY MARKET

4.1.3.

HYSTEROSCOPY MARKET

4.1.4.

IMAGING TESTING MARKET

4.1.5.

OVARIAN RESERVE TESTING MARKET

4.1.6.

HORMONAL LEVEL TESTING MARKET

4.1.7.

ENETIC TESTING MARKET

4.1.8.

OTHERS

4.2.

4.2.GLOBAL MALE INFERTILITY MARKET BY TREATMENT

4.2.1.

DRUGS AND MEDICINE MARKET

4.2.2.

SURGICAL MARKET

4.2.3.

INTRAUTERINE INSEMINATION (IUI) MARKET

4.2.4.

ASSISTED REPRODUCTIVE TECHNOLOGY (ART) MARKET

4.2.5.

OTHERS

5. COMPETITIVE LANDSCAPE 5.1.

KEY STRATEGY ANALYSIS

5.2.

KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS 6.1.

NORTH AMERICA

6.1.1.

UNITED STATES

6.1.2.

CANADA

6.1.3.

REST OF NORTH AMERICA

6.2.

EUROPE

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research 6.2.1.

UNITED KINGDOM

6.2.2.

FRANCE

6.2.3.

GERMANY

6.2.4.

ITALY

6.2.5.

SPAIN

6.2.6.

REST OF EUROPE

6.3.

ASIA PACIFIC

6.3.1.

INDIA

6.3.2.

CHINA

6.3.3.

JAPAN

6.4.

REST OF THE WORLD

7. COMPANY PROFILES 7.1.BAYER AG 7.1.1.

Introduction

7.1.2.

BAYER AG PRODUCT PORTFOLIO

7.1.3.

BAYER AG RECENT ACTIVITIES

7.2.

BRISTOL-MYERS SQUIBB CO.

7.2.1.

INTRODUCTION

7.2.2.

BRISTOL-MYERS SQUIBB CO. PRODUCT PORTFOLIO

7.2.3.

BRISTOL-MYERS SQUIBB CO. RECENT ACTIVITIES

7.3.

CHURCH & DWIGHT COMPANY INC.

7.3.1.

INTRODUCTION

7.3.2.

CHURCH & DWIGHT COMPANY INC. PRODUCT PORTFOLIO

7.3.3.

CHURCH & DWIGHT COMPANY INC. RECENT ACTIVITIES

7.4.

COOK MEDICAL, INC.

7.4.1.

INTRODUCTION

7.4.2.

COOK MEDICAL, INC. PRODUCT PORTFOLIO

7.4.3.

COOK MEDICAL, INC. RECENT ACTIVITIES

7.5.

COOPERSURGICAL INC.

7.5.1.

INTRODUCTION

7.5.2.

COOPERSURGICAL INC. PRODUCT PORTFOLIO

7.5.3.

COOPERSURGICAL INC. RECENT ACTIVITIES

7.6.

ELI LILLY & CO.

7.6.1.

INTRODUCTION

7.6.2.

ELI LILLY & CO. PRODUCT PORTFOLIO

7.6.3.

ELI LILLY & CO. RECENT ACTIVITIES

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research 7.7.

EMD SERONO, INC

7.7.1.

INTRODUCTION

7.7.2.

EMD SERONO, INC PRODUCT PORTFOLIO

7.7.3.

EMD SERONO, INC RECENT ACTIVITIES

7.8.

ENDO PHARMACEUTICALS INC.

7.8.1.

INTRODUCTION

7.8.2.

ENDO PHARMACEUTICALS INC. PRODUCT PORTFOLIO

7.8.3.

ENDO PHARMACEUTICALS INC. RECENT ACTIVITIES

7.9.

FERRING PHARMACEUTICALS

7.9.1.

INTRODUCTION

7.9.2.

FERRING PHARMACEUTICALS PRODUCT PORTFOLIO

7.9.3.

FERRING PHARMACEUTICALS RECENT ACTIVITIES

7.10.

GENEA

7.10.1. INTRODUCTION 7.10.2. GENEA PRODUCT PORTFOLIO 7.10.3. GENEA RECENT ACTIVITIES 7.11.

GLAXOSMITHKLINE PLC

7.11.1. INTRODUCTION 7.11.2. GLAXOSMITHKLINE PLC PRODUCT PORTFOLIO 7.11.3. GLAXOSMITHKLINE PLC RECENT ACTIVITIES 7.12.

HALOTECH DNA

7.12.1. INTRODUCTION 7.12.2. HALOTECH DNA PRODUCT PORTFOLIO 7.12.3. HALOTECH DNA RECENT ACTIVITIES 7.13.

IRVINE SCIENTIFIC

7.13.1. INTRODUCTION 7.13.2. IRVINE SCIENTIFIC PRODUCT PORTFOLIO 7.13.3. IRVINE SCIENTIFIC RECENT ACTIVITIES 7.14.

JANSSEN PHARMACEUTICAL

7.14.1. INTRODUCTION 7.14.2. JANSSEN PHARMACEUTICAL PRODUCT PORTFOLIO 7.14.3. JANSSEN PHARMACEUTICAL RECENT ACTIVITIES 7.15.

MERCK SERONO

7.15.1. INTRODUCTION 7.15.2. MERCK SERONO PRODUCT PORTFOLIO 7.15.3. MERCK SERONO RECENT ACTIVITIES

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research 7.16.

NOVARTIS INTERNATIONAL AG

7.16.1. INTRODUCTION 7.16.2. NOVARTIS INTERNATIONAL AG PRODUCT PORTFOLIO 7.16.3. NOVARTIS INTERNATIONAL AG RECENT ACTIVITIES 7.17.

ORIGIO

7.17.1. INTRODUCTION 7.17.2. ORIGIO PRODUCT PORTFOLIO 7.17.3. ORIGIO RECENT ACTIVITIES 7.18.

OVASCIENCE

7.18.1. INTRODUCTION 7.18.2. OVASCIENCE PRODUCT PORTFOLIO 7.18.3. OVASCIENCE RECENT ACTIVITIES 7.19.

PFIZER INC.

7.19.1. INTRODUCTION 7.19.2. PFIZER INC. PRODUCT PORTFOLIO 7.19.3. PFIZER INC. RECENT ACTIVITIES 7.20.

PRINCETON BIOMEDITECH CORP.

7.20.1. INTRODUCTION 7.20.2. PRINCETON BIOMEDITECH CORP. PRODUCT PORTFOLIO 7.20.3. PRINCETON BIOMEDITECH CORP. RECENT ACTIVITIES

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research

REPORT SUMMARY The Global Female Infertility Diagnosis and Treatment market has been growing significantly and expected to hit $XXXX million by 2022 at a CAGR of XX % during 2017-2022. The major factors contributing to the growth of female infertility diagnosis and treatment market includes changing life style of the young and middle age population and increasing IVF market. Furthermore, increasing female geriatric population and rising trend of surrogacy, growing infertility rate among female globally are also estimated to fuel the growth of the market. Infertility in young women is increasing continuously across the globe. Infertility can be defined as not being able to get pregnant after one year of trying (or 6 months, if a woman is 35 or older). Additional, women who can get pregnant but are unable to stay pregnant is considered as infertile too.

The female infertility diagnosis and treatment finds a vital scope during the forecast period. The major factors that are augmenting the growth of the market are increasing geriatric population, and increasing infertility rate among women. High cost of treatment, increasing incidences of treatment failures and social stigma related to infertility treatment will restrain the growth of the global female infertility diagnosis and treatment market.

A trend has been observed that the average age of having a child has been increasing in the large economies due to various reasons. With the increase in age, the probability of having a child decreases due to hormonal changes. This factor will grow the market, as middle age population is increasing globally. In 2016, about 10.2% of the total global population comprises women aged 30 to 45 years. A number of major economies have higher percentages of middle age(30-45 years) female population such as China 11% , the US 10%, the UK 10.5%, and Japan 10%, and this will grow the market in upcoming time period. On the basis of geography, female infertility diagnosis and treatment market is segmented into North America, Asia Pacific, Europe and Rest of the World. In the current scenario, North America region will be the largest market globally. Countries such as the US and Canada will have the largest market share. Increasing female middle-aged population in the region and changing lifestyle are some of the major factors driving the growth of the market. In the US, about 40 million people are aged 65 and older, and it is further estimated to reach 72 million by 2030, and more than 85 million by the year 2050. The U.S. is expected to grow at a CAGR of XXXX % during the forecast period. Increasing IVF market is also one of the major factors driving the growth of the market in the region.

Asia Pacific is estimated to be the fastest growing region during the forecast period. Increasing medical tourism in Asia and increasing geriatric population in China and Japan are estimated to be the major factors driving the growth of the market. In APAC, countries like China, India, and Japan will be the market leaders, which will show a vital growth in the upcoming time period. Large percentage of geriatric population in Japan and China, increasing government investment, and increasing disposable income of the countries are the major factors, which will propel the growth of the market. APAC is expected show a growth rate of XXXX % CAGR during the forecast period. A vital growth is expected in Europe. Europe is expected to hit $XXXX million at a CAGR XX%. The major reason for the growth of the market are increasing geriatric population in the countries such as the UK (17%), Germany (21.4%), and Italy (22%), changing lifestyle and increasing infertility rate in women. The major markets of the European Union will be the UK, France, Spain, Germany, and Italy.

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research Key players of the female infertility diagnosis and treatment market include Bayer Ag, Bristol-Myers Squibb Co, Church & Dwight Company Inc., Cook Medical Inc., Coopersurgical Inc., Eli Lilly & Co., EmdSeronoInc, Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Genea, GlaxoSmithKline Plc., Halotech DNA, Irvine Scientific, Janssen Pharmaceutical, Merck Serono, Novartis International Ag, Origio, Ovascience, Pfizer Inc., and Princeton. Mergers and acquisitions, contracts and agreements, new product launches, and geographical expansion are the major strategies adopted by the market players to strengthen their market share globally.

GLOBAL FEMALE INFERTILITY TREATMENT MARKET RESEARCH AND ANALYSIS, BY REGION 2015-2022 ($ MILLION) Region

2015

2016

2017

2018

2019

2020

2021

2022

CAGR% 2017-2022

North America Europe Asia pacific RoW Total

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

XXXX XXXX XXXX XXXX XXXX

Source: OMR Analysis

RESEARCH METHODS AND TOOLS The data is refined through our secondary and primary research.

Secondary Research

Refining Secondary Data

Primary Research

• A team devoted to track down trends in the industry, company documents and financials • Studying government and non-government organization, laws and regulations, tracking down policies and tax laws.

• A team of experts refines all the data available to derive the market segments, share of each market segment, total market size and final CAGR. • Primary researh involves tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.

MARKET BREAKDOWN

BY SEGMENTS

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research Female infertility diagnosis and treatment market is segmented by product into two major segments i.e. by diagnosis and by treatment. The market is expected to show a vital growth at a CAGR of XXXX % during the forecast period.

On the basis of diagnosis, the female infertility diagnosis and treatment market can be segmented into Ovulation Testing Market, Hysterosalpingography Market, Hysteroscopy Market, Imaging Testing Market, Ovarian Reserve Testing Market, Hormonal Level Testing Market, Genetic Testing Market, and others. By Treatment, the infertility diagnosis market can be segmented as drugs and medicine market, surgical market, Intrauterine Insemination (IUI) Market, assisted reproductive technology (art) market and others.

A vital growth in female infertility diagnosis and treatment market will be seen globally. North America region will be the largest market globally. Countries such as the US and Canada will be the largest markets. Increasing female geriatric population in the region and changing lifestyle is one of the major factors driving the growth of the market. In the US, about 40 million people are aged 65 and older, and it is further estimated to reach 72 million by2030 and more than 85 million by 2050.

The U.S. is expected to grow at a CAGR of XXXX % during the forecast period. Increasing IVF market is also one of the major factors driving the growth of the market in the region.

Asia Pacific is estimated to be the fastest growing region during the forecast period. Increasing medical tourism in Asia and increasing geriatric population in China and Japan are estimated to be the major factors driving the growth of the market. In APAC, countries like China, India, and Japan will be the markets, which will show a vital growth in the upcoming time period. Large percentage of geriatric population in Japan and China, increasing government investment, and increasing disposable income of the countries are the major factors, which will grow the market. APAC is expected show a growth rate of XXXX% CAGR during the forecast period. A vital growth is expected in Europe. Europe is expected to hit $XXXX million at a CAGR XX%. The major reason for the growth of the market are increasing geriatric population in the countries such as UK (17%), Germany (21.4%), and Italy (22%), changing lifestyle, and increasing infertility rate in women. The major markets of the European Union include the UK, France, Spain, Germany, and Italy.

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research MARKET DETERMINANT MOTIVATORS GROWING INFERTILITY RATE AMONG FEMALE Infertility in young women is increasing continuously across the globe. Infertility can be defined as not being able to get pregnant after 1 year of trying (or 6 months if a woman is 35 or older).

Additional, women who can get pregnant but are unable to stay pregnant is considered as infertile too. According to the Centers for Disease Control and Prevention (CDC) more than 10% of women population i.e. 6.1 million in the US ages 15-44 have difficulty getting pregnant or staying pregnant.

Female infertility factors contribute to approximately 50% of all infertility cases, and female infertility alone accounts for approximately one-third of all infertility cases. The female infertility can be caused due to several reasons some of them are as follows:  Damage to fallopian tubes: The function of the fallopian tubes is to carry eggs from the ovaries to the uterus. If this process gets effected, the contact between the egg and the sperm is restricted. The fallopian tube can be damaged from surgeries such as pelvic infections, endometriosis, and pelvic surgeries.  Improper Hormonal Changes: At the time of ovulation, women suffer from various problems such as no release of an egg from the ovary and thickening of the endometrium (lining of the uterus) in the preparation for the fertilized egg. The problems may be detected using body temperature charts, ovulation predictor kits, and blood tests to detect hormone levels.  Cervical Problems: Due to the production of mucus or a previous surgical procedure performed in cervical canal, the sperm couldn’t go through the cervical canal.  Epileptic: Epileptic seizures can cause an increase in the serum prolactin level and fluctuation in women’s reproductive hormones. The chance of infertility is high in epileptic females.

About 50% of the female population is reported to have menstrual abnormalities and irregular ovulation cycle; this can cause an indirect pregnancy problems or infertility.  Endometriosis: When the endometrial tissue implants and develops outside of the uterus, it affects the function of the ovaries, uterus, and fallopian tubes, and due to this, pregnancy complications may arise in a woman.

Polycystic Ovary Syndrome (PCOS): It is caused due to imbalance hormones in a woman’s reproductive system, which results less production of eggs and thus decreases the chances of getting pregnant.

One of the major reason for the growing infertility rate among women is growing average age of becoming parent and this population contains a high percentage globally. In 2016, according to the World Bank and OMR analysis, more than 265 million women were middle aged i.e. 30 to 45,and this is expected to increase because of the population in countries like China and India due to the reason that at present; the percentage of young population is quite high. With the increasing population, hormonal changes in women are observed, and their capability to give birth decreases, and this will drive the market in positive direction.

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research

MIDDLE AGE FEMALE POPULATION (30-45 YEARS) PERCENTAGE W.R.T. TO OVERALL POPULATION (2016)

11

10.5 10.2 10

Chi na

US

10

UK

Japa n

Indi a

Source: OMR Analysis & World Bank

With various techniques, the infertility in female can be diagnosed and cure. The treatment for the infertility includes Assisted Reproductive Technology or ART, in vitro fertilization, medical therapy, intrauterine insemination, egg donation, ZIFT, and GIFT.

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research MARKET SEGMENTATION GLOBAL FEMALE INFERTILITY MARKET BY DIAGNOSIS HYSTEROSALPINGOGRAPHY MARKET Increasing infertility in female population and changing lifestyles are the major causes of market growth rate. The global hysterosalpingography market is expected to hit $XXXX million by 2022, growing at a CAGR XX% during the forecast period. Hysterosalpingography is also known as uterosalpingography. Hysterosalpingography is an x-ray examination with the help of which, woman's uterus and fallopian tubes are examined. It is a non-invasive medical test, with the help of which diagnosis and treatment of infertile women is possible.

The technique used in Hysterosalpingography is Fluoroscopy. It is a special x-ray technique that makes it possible to see internal organs in motion. During the inspection, the uterus and fallopian tubes are filled with a water-soluble contrast material. With the help of fluoroscopy, the anatomy and functions of the body parts are analysed. Additional to this, the miscarriages due to abnormalities within the uterus and to determine the presence and severity of tumour masses, adhesions and uterine fibroids are also observed. The benefit of Hysterosalpingography is that it is a minimum invasive procedure and x-rays have no side-effects. It is a short and fast process, which can provide variety of information about abnormalities. Although some risks are associated with the process, Hysterosalpingography can occasionally open fallopian tubes that are blocked, allowing the patient to become pregnant afterwards. There is always a minimum chance of cancer due to excessive exposer of radiation. The Hysterosalpingography diagnosis market will have a considerable market share globally in the coming forecas period. The US will dominate the market due to reasons like favorable reimbursement policies and government support. The United States Equestrian Federation conducts works shops to discuss the use of medroxyprogesteroneto and solves the various concerns raised on its use. In the developing economy of APAC; such as China and India, the government is not concerned about the infertility between the people as these economies are already facing population related problems in their nation. Some major market players in hysterosalpingogram are Fairview Health Services,, Summit Medical Group , Shady Grove Fertility, Southwest Medical Center, Atlantic OB-GYN, TRA-MINW, Reproductive Medicine Institute, and South Florida Institute for Reproductive Medicine.

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research COMPANY PROFILE ELI LILLY & CO. Lilly Corporate Center Indianapolis, Indiana 46285, USA phone: +1-317-276-2000 Website: www.lilly.com ELI LILLY & CO. INTRODUCTION The company was founded in 1876, and have more than 40, 000 employees. The company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The product portfolio of the company includes human pharmaceutical products and animal health products as two major segments. The company’s portfolio includes treatments in the areas of oncology, cardiovascular, diabetes, endocrine critical care, neuroscience, men’s health, and musculoskeletal fields. For endocrine, the company is providing Humatrope, a medicine for the growth of the hormone.

ELI LILLY & CO. PRODUCT PORTFOLIO Product Humatrope (somatropin [rDNAorigin] for injection)

Description The product is of endocrine stream. The product is for patients who have growth hormone deficiency in adulthood or in childhood. In adulthood, this deficiency can be due to pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma. Mostly, it is taken by injecting to a patient.

Source: Company Website

ELI LILLY & CO. RECENT ACTIVITIES Date September 2017

Activity Disinvestment

July 2017

Partnership

July 2017

Expansion

Details The company offers voluntary early retirement to more than 3500 employees so that the fixed cost of the company can be decreased worldwide.

The company has gone into collaboration with Nektar Therapeutics for NKTR-358. NKTR-358 is a novel immunological therapy discovered by Nektar. It has potential to potential to treat a number of autoimmune and other chronic inflammatory conditions.

The company started sale of Olumiant (baricitinib) 2-mg and 4-mg tablets in Japan for the treatment of rheumatoid arthritis (RA) after they got permission from Japan Ministry of Health, Labor and Welfare (MHLW).

Source: Company Website

ABOUT US

All Rights Reserved

Global Female Infertility Diagnosis and Treatment Market Research and Analysis, 20152022 Orion Market Research

Orion Market Research provides market research and consulting services. At OMR we strive to deliver quality reports that are based on a 360degree analysis of the market factors. We provide qualitative and quantitative analysis of the market. We serve clients from 16 different domains which includes healthcare, biotechnology, chemical, agriculture and information technology. We work to add more to our array of clients, services and products.

At the moment OMR provides 4 services; i. Industry Reports ii. Consulting iii. Custom Reports iv. Company Profiling Market research and consulting is a highly competitive market. There are number of companies which provide top quality reports and analysis. At OMR we believe in overcoming the competition by delivering timely and quality reports. The Orion in our names signifies our attempt to create a place for ourselves amongst a galaxy of market research companies.

Thank You for being with us and believing in us.

CONTACT US Orion Market Research Pvt Ltd 116, Shagun Arcade Indore, Madhya Pradesh India- 452001 Email: info@omrglobal.com

Website: www.omrglobal.com

All Rights Reserved

Phone: +91-9179828694